Substance / Medication

Flutamide

Overview

Active Ingredient

flutamide

RxNorm CUI

4508

Indications

® 2 2 Eulexincapsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B-C and Stage Dmetastatic carcinoma of the prostate.

Labeler: Waylis Therapeutics LLCUpdated: 2025-02-04T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

® ® Eulexincapsules are contraindicated in patients who are hypersensitive to Eulexinor any component of this preparation. ® Eulexincapsules are contraindicated in patients with severe hepatic impairment (baseline hepatic enzymes should be evaluated prior to treatment).

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of prostate

Hirsutism

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Evaluation of Eflornithine on Facial and Forearm Skin

NCT00152048Phase 4Completed78 enrolled

Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS

NCT00428311Phase 4Completed50 enrolled

Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism

NCT01817894Phase 4Completed22 enrolled

Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female

NCT06976424Phase 4Recruiting122 enrolled

View all 4 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.

Dumesic Daniel A, Winnett Chloe, Lu Gwyneth et al. · Fertil Steril · 2023

PMID: 36400597RCTFull text (PMC)

Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.

Madan Ravi A, Bilusic Marijo, Stein Mark N et al. · Oncologist · 2023

PMID: 37134294RCTFull text (PMC)

Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia.

Faghihi Gita, Iraji Fariba, Siadat Amir Hossein et al. · J Cosmet Dermatol · 2022

PMID: 35152531RCT

Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.

Díaz M, Gallego-Escuredo J M, de Zegher F et al. · Diabetes Metab · 2016

PMID: 26546387RCT

Elevated level of 17β-estradiol is associated with overexpression of FSHR, CYP19A1, and CTNNB1 genes in porcine ovarian follicles after prenatal and neonatal flutamide exposure.

Grzesiak M, Knapczyk-Stwora K, Duda M et al. · Theriogenology · 2012

PMID: 23043943RCT

Morphological and functional alterations in adult boar epididymis: Effects of prenatal and postnatal administration of flutamide.

Lydka Marta, Kopera-Sobota Ilona, Kotula-Balak Malgorzata et al. · Acta Vet Scand · 2011

PMID: 21342526RCTFull text (PMC)

Differential expression of connexin 43 in adult pig testes during normal spermatogenic cycle and after flutamide treatment.

Kopera I, Durlej M, Hejmej A et al. · Reprod Domest Anim · 2011

PMID: 21457361RCT

Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.

Vinaixa Maria, Rodriguez Miguel Angel, Samino Sara et al. · PLoS One · 2011

PMID: 22194988RCTFull text (PMC)

Divergent effects of ethinylestradiol-drospirenone and flutamide-metformin on follistatin in adolescents and women with hyperinsulinemic androgen excess.

Ibáñez Lourdes, Díaz Marta, López-Bermejo Abel et al. · Gynecol Endocrinol · 2011

PMID: 20528210RCT

Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.

Ibáñez Lourdes, López-Bermejo Abel, Díaz Marta et al. · Gynecol Endocrinol · 2010

PMID: 20500100RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Flutamide (substance)
SNOMED CT: 387587007
UMLS CUI: C0016384
RxNorm CUI: 4508
Labeler: Waylis Therapeutics LLC

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.